Low-Dose Naltrexone for Endometriosis:A Neuroimmune Approach to Chronic Pelvic Pain

Yoon Hang Kim, MD, MPH

Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Low-dose naltrexone (LDN) is used off-label for the conditions discussed. Always consult a qualified healthcare provider before starting or modifying any treatment.

Introduction: Endometriosis as a Systemic Neuroimmune Disorder

Endometriosis affects approximately 10% of reproductive-age individuals assigned female at birth, and it is identified as the underlying cause in 40–87% of those with chronic pelvic pain (CPP). Despite its prevalence and profound impact on quality of life, effective pain management remains one of the most elusive challenges in gynecologic care. Conventional approaches—hormonal suppression with combined oral contraceptives, progestins, or GnRH agonists/antagonists, and surgical excision—address disease-specific pathology but often fail to resolve pain completely. This treatment gap has spurred interest in adjunctive therapies that target the underlying mechanisms driving pain persistence, particularly the phenomenon of central sensitization.

What has become increasingly clear is that endometriosis is not merely a localized pelvic disease. It is a systemic inflammatory and neuroimmune condition. Persistent nociceptive input from ectopic endometrial lesions triggers peripheral sensitization, which over time drives neuroinflammatory changes in the central nervous system—a progression from nociceptive to neuropathic to nociplastic pain. A 2026 cross-sectional study published in BMC Women's Health found that central sensitization, measured by the Central Sensitization Inventory (CSI), was present in over 52% of clients with endometriosis, with prevalence increasing significantly when symptoms had persisted for more than five years. This is precisely the landscape in which low-dose naltrexone (LDN) may offer a meaningful therapeutic contribution.

In my clinical practice (www.directintegrativecare.com), I regard endometriosis-associated pain through this integrative neuroimmune lens. LDN is not a replacement for hormonal management or skilled excision surgery. It is, however, a compelling adjunctive tool—one that addresses the neuroinflammatory and central sensitization mechanisms that conventional therapies often leave untouched.

Understanding Endometriosis-Associated Pain: Beyond the Lesion

The traditional model of endometriosis pain posits a direct relationship between lesion burden and symptom severity. Clinical experience and a growing body of research have challenged this model. Many clients with minimal lesion burden experience debilitating pain, while some with extensive disease report relatively few symptoms. The disconnect arises because endometriosis-associated pain is multi-mechanistic, arising from at least three distinct but overlapping processes.

Nociceptive pain results from tissue damage and local inflammation at the site of endometriotic implants. Activated peritoneal macrophages secrete elevated levels of pro-inflammatory cytokines—tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6)—which promote lesion growth, angiogenesis, and local nerve fiber sensitization. Research has consistently demonstrated that TNF-α concentrations are elevated in both peritoneal fluid and serum of individuals with endometriosis, and higher concentrations correlate with disease stage and active lesion status.

Neuropathic pain emerges when endometriotic lesions infiltrate or compress pelvic nerves, or when pain mediators released by lesions directly damage somatosensory neural tissue. Endometriotic lesions develop their own sensory and sympathetic nerve supply—a process called neurogenesis—which creates additional pain signaling pathways independent of the original tissue injury.

Nociplastic pain represents the most insidious dimension. Defined as pain arising from altered nociception without clear evidence of actual or threatened tissue damage, nociplastic pain results from central nervous system sensitization. Chronic nociceptive input from the pelvis, combined with neurogenic inflammation, eventually remodels central pain processing circuits. The result is widespread pain amplification, visceral hypersensitivity, and the emergence of comorbid central sensitivity syndromes—fibromyalgia, irritable bowel syndrome, interstitial cystitis/bladder pain syndrome, and vulvodynia. It is this central sensitization that explains why many clients continue to experience severe pain even after successful surgical excision of all visible disease.

The clinical implication is clear: treating only the lesion is often insufficient. A comprehensive approach must also address the neuroinflammatory processes that sustain and amplify pain at the level of the central nervous system. This is the therapeutic niche where LDN becomes relevant.

What Is Low-Dose Naltrexone?

Naltrexone is an opioid receptor antagonist approved by the FDA at 50 mg/day for the treatment of opioid and alcohol use disorders. At this standard dose, naltrexone produces sustained, near-complete blockade of mu-opioid receptors lasting 24–72 hours. Low-dose naltrexone refers to the off-label use of naltrexone at doses typically ranging from 1.5 to 4.5 mg/day—approximately one-tenth of the standard dose.

This dose distinction is critical because LDN operates through entirely different mechanisms than standard-dose naltrexone. At low doses, the opioid receptor blockade is transient and incomplete, lasting only 4–6 hours when taken at bedtime. This brief blockade triggers a compensatory rebound in endogenous opioid production—beta-endorphin, met-enkephalin, and opioid growth factor (OGF)—that persists throughout the following day. Additionally, LDN exerts anti-inflammatory effects through pathways that are independent of its opioid receptor activity.

LDN requires a prescription and is prepared by compounding pharmacies, as no commercial formulation exists at these low doses. It is typically taken as a single oral dose at bedtime, and most protocols involve a gradual titration—often starting at 0.5–1.5 mg/day and increasing by 0.5–1.5 mg every one to two weeks until the target dose is reached. A 2024 observational study found that maximally effective doses varied considerably among individuals, ranging from 0.1 mg to approximately 5.6 mg/day, with many reporting optimal benefit at 2 mg/day or below—underscoring the importance of individualized dose-finding.

Proposed Mechanisms of Action: Why LDN Makes Sense for Endometriosis

The rationale for using LDN in endometriosis rests on three interconnected pharmacological mechanisms, each of which targets a distinct aspect of the disease's neuroimmune pathophysiology.

Mechanism 1: Toll-Like Receptor 4 (TLR4) Antagonism and Microglial Modulation

Naltrexone and its stereoisomers antagonize Toll-like receptor 4 (TLR4), a pattern recognition receptor expressed on microglial cells in the central nervous system and on peripheral macrophages. TLR4 activation by endogenous damage signals or bacterial lipopolysaccharides triggers an inflammatory cascade—NF-κB activation, release of TNF-α, IL-1β, IL-6, nitric oxide, and excitatory amino acids—that drives neuroinflammation, glial cell activation, and central sensitization.

In endometriosis, the same pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) that are elevated in peritoneal fluid and secreted by dysregulated peritoneal macrophages also circulate systemically and contribute to central nervous system inflammation. By antagonizing TLR4, LDN reduces microglial activation and attenuates the neuroinflammatory milieu that sustains nociplastic pain. In vitro research has demonstrated that naltrexone at concentrations corresponding to low-dose ranges induces anti-inflammatory M2 polarization in BV-2 microglial cells and favorably modifies cellular energy homeostasis in neuroinflammatory conditions.

The relevance to endometriosis is direct: the same TLR4/NF-κB/cytokine axis that LDN modulates centrally is overactivated both locally in the peritoneum and systemically in clients with endometriosis. LDN may therefore interrupt the feed-forward loop between peripheral inflammation and central sensitization.

Mechanism 2: Endogenous Opioid Upregulation (The Rebound Effect)

The transient opioid receptor blockade produced by bedtime LDN triggers a compensatory upregulation of both opioid receptor density and endogenous opioid production. Animal studies have demonstrated that daily naltrexone administration increases brain opioid receptor density by approximately 1.9-fold within eight days, primarily affecting mu and delta receptor subtypes. The resulting rebound surge in beta-endorphin, met-enkephalin, and OGF provides enhanced endogenous analgesia, and these endorphins also serve immunomodulatory functions—modulating NK cell activity, T-cell responses, and cytokine balance.

For clients with endometriosis, this mechanism is relevant on two levels. First, the analgesic rebound directly improves pain modulation. Second, the immunomodulatory effects of elevated endogenous opioids may help counteract the immune surveillance failures (impaired NK cell cytotoxicity, macrophage polarization imbalances) that allow ectopic endometrial tissue to implant and persist.

Mechanism 3: Peripheral Inflammatory Cytokine Modulation

Beyond its central effects, LDN influences peripheral immune signaling. Clinical studies in conditions such as fibromyalgia and Crohn's disease have documented measurable reductions in circulating pro-inflammatory cytokine levels during LDN therapy. Given that endometriosis is characterized by elevated peritoneal and systemic TNF-α, IL-6, and IL-8—cytokines that promote lesion survival, angiogenesis, and peritoneal adhesion—peripheral cytokine modulation by LDN represents a theoretically coherent mechanism for influencing disease activity as well as pain.

Current Clinical Evidence: What We Know and What We Don't

Intellectual honesty demands acknowledging that LDN has not yet been proven as an endometriosis-specific pain treatment in completed, published randomized controlled trials. The evidence base is emerging, and it draws on several categories of data.

The Penn State Phase III Trial (NCT03970330) is the most disease-specific investigation to date. This randomized, quadruple-blinded, placebo-controlled trial was designed to evaluate whether adding LDN to standard hormonal suppression (norethindrone acetate) improves endometriosis-associated pain as measured by daily Visual Analogue Scale scores and validated quality-of-life instruments (EHP-30, PGIC). The trial's status is listed as terminated, and detailed results have not yet been published—a reminder that rigorous clinical evidence takes time to generate and that not every promising trial reaches completion.

Evidence from overlapping chronic pain conditions is more robust. A 14-year retrospective analysis at the Mayo Clinic (2023) involving 115 patients prescribed LDN for chronic pain conditions found that 65% of those with follow-up data reported perceived benefit in pain symptoms. The most common dose was 4.5 mg once daily, adverse effects were reported in only 11% of clients, and concomitant analgesic medications—including opioids—did not affect perceived benefit or discontinuation rates.

A scoping review published in Pain Medicine (2023) systematically evaluated LDN's utility for non-cancer centralized pain conditions and concluded that LDN shows promise for conditions characterized by central sensitization and neuroinflammation—the very mechanisms now understood to underlie chronic endometriosis-associated pain. The review emphasized LDN's favorable safety profile and its mechanism of TLR4 antagonism on microglial cells as a distinguishing pharmacological feature.

A comprehensive 2026 review in the Journal of Personalized Medicine synthesized the available preclinical and clinical data and confirmed that LDN's proposed mechanisms—transient opioid receptor blockade, TLR4 antagonism, and neuroimmune modulation—are well-supported by preclinical evidence and consistent with symptom improvements observed across multiple chronic pain conditions. However, the review appropriately noted that microglial modulation in human chronic pain populations treated with LDN remains an indirectly supported mechanism, as no clinical trials to date have included biomarker or neuroimaging confirmation of reduced microglial activation.

Additional supporting evidence comes from LDN's documented efficacy in conditions that frequently co-occur with endometriosis—fibromyalgia, vulvodynia, and chronic fatigue—conditions that share the central sensitization phenotype. A 2025 case series demonstrated symptomatic improvement with LDN in vulvodynia, a common comorbidity in endometriosis clients, further reinforcing the clinical plausibility of LDN's role in pelvic pain management.

Clinical Integration: How LDN Fits into Endometriosis Care

In my practice, LDN is not positioned as a standalone treatment for endometriosis. It is used as an adjunctive therapy within a comprehensive, individualized treatment plan that may include hormonal management, dietary and lifestyle optimization, targeted supplementation, and coordination with surgical specialists when excision is indicated.

The clients most likely to benefit from LDN are those whose pain has features of central sensitization: widespread pain extending beyond the pelvis, pain that persists despite adequate hormonal suppression or successful surgery, comorbid central sensitivity syndromes (fibromyalgia, IBS, bladder pain syndrome), and symptoms suggesting neuroinflammation—fatigue, cognitive dysfunction, sleep disruption, and mood disturbance accompanying their pelvic pain.

Typical dosing begins at 0.5–1.5 mg at bedtime, with gradual titration over several weeks. Response assessment should extend beyond simple pain scores to include functional capacity, sleep quality, fatigue, and validated quality-of-life measures. Clinical experience suggests that meaningful response typically requires 8–12 weeks, consistent with the time course needed for endogenous opioid upregulation and neuroinflammatory modulation to take effect.

Important clinical considerations include the requirement that clients discontinue any concurrent opioid medications before starting LDN, as naltrexone will precipitate withdrawal in opioid-dependent individuals. The most commonly reported side effect is vivid dreams, which typically resolve with continued use. LDN is contraindicated in pregnancy, and clients of reproductive age must use reliable contraception during treatment.

Safety Profile and Tolerability

One of LDN's most compelling features is its safety profile. Across published studies and clinical experience, serious adverse events are rare. The most frequently reported side effects—vivid dreams, mild headache, and transient nausea—are generally self-limiting and often resolve within the first two to four weeks of therapy. In the Mayo Clinic retrospective, adverse effects were reported in only 11% of clients, and the discontinuation rate of 36% was attributable to a variety of factors, not primarily adverse effects.

LDN does not produce dependence, tolerance, or withdrawal. It does not suppress immune function—a critical distinction from many immunosuppressive agents used in autoimmune and inflammatory conditions. Its mechanism of immune modulation, rather than immune suppression, makes it particularly attractive for clients who are wary of the long-term effects of immunosuppressive therapies.

As an inexpensive, compounded oral medication taken once daily, LDN also addresses the accessibility dimension of chronic disease management. Many clients with endometriosis face years of diagnostic delay and treatment frustration; an affordable, well-tolerated adjunctive option with a favorable risk-benefit profile can meaningfully improve the therapeutic relationship and treatment adherence.

Future Directions and the Need for Rigorous Research

The most significant limitation of LDN in endometriosis care is the absence of completed, adequately powered randomized controlled trials specific to this condition. While the mechanistic rationale is strong and the supporting evidence from related conditions is encouraging, endometriosis-specific efficacy data remain preliminary. The terminated Penn State trial underscores both the importance and the difficulty of conducting rigorous RCTs in this population.

Future research priorities should include adequately powered RCTs evaluating LDN as an adjunct to standard endometriosis care, with pain outcomes stratified by pain phenotype (nociceptive, neuropathic, nociplastic); biomarker studies measuring changes in circulating cytokines (TNF-α, IL-6, IL-1β), endogenous opioid levels, and central sensitization indices during LDN therapy; neuroimaging studies (e.g., PET ligand studies of microglial activation) to confirm or refute the hypothesized central anti-inflammatory mechanism in human subjects; and dose-optimization studies that account for the significant inter-individual variability in effective dosing documented in recent observational research.

Until this evidence matures, LDN should be regarded as an experimental, symptom-focused adjunctive therapy—one with strong mechanistic plausibility, a favorable safety profile, and growing (if still incomplete) clinical support.

Conclusion

Endometriosis-associated chronic pelvic pain is a multi-mechanistic condition that demands a multi-mechanistic therapeutic approach. Low-dose naltrexone, through its unique combination of TLR4 antagonism, endogenous opioid upregulation, and peripheral cytokine modulation, directly addresses the neuroinflammatory and central sensitization processes that perpetuate pain beyond the scope of surgical and hormonal interventions alone.

While definitive endometriosis-specific trial data are still needed, the convergence of preclinical evidence, clinical data from related centralized pain conditions, and a well-established safety profile make LDN a rational and increasingly well-supported adjunctive option for appropriately selected clients. As the field continues to evolve, LDN exemplifies the kind of integrative, mechanism-informed approach that moves beyond symptom suppression toward genuine neuroimmune rebalancing.

If you are living with endometriosis-associated pain and are interested in exploring whether LDN may be appropriate for your situation, I encourage you to schedule a consultation with a physician experienced in both integrative medicine and LDN prescribing. In my practice (www.directintegrativecare.com), I work collaboratively with each client to develop personalized, evidence-informed treatment plans that honor the complexity of this condition.

References

1. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451-459. PMID: 24526250.

2. Driver CN, D'Souza RS. Efficacy of low-dose naltrexone and predictors of treatment success or discontinuation in fibromyalgia and other chronic pain conditions: a fourteen-year, enterprise-wide retrospective analysis. Biomedicines. 2023;11(4):1087. doi:10.3390/biomedicines11041087.

3. Rupp A, Young E, Chadwick AL. Low-dose naltrexone's utility for non-cancer centralized pain conditions: a scoping review. Pain Med. 2023;24(11):1270-1281. doi:10.1093/pm/pnad074.

4. Marcus DA, Robbins A, Araki A, et al. Effective doses of low-dose naltrexone for chronic pain—an observational study. J Pain Res. 2024;17. PMID: 38532991.

5. Biasioli A, Previtera F, Mazzera I, et al. Central sensitization in women with endometriosis: a cross-sectional study. BMC Womens Health. 2026;26:174. doi:10.1186/s12905-026-04348-8.

6. Karp BI, Stratton P. Endometriosis-associated chronic pelvic pain. Med (N Y). 2023;4(3):143-146. PMID: 36858044.

7. McNamara HC, Frawley HC, Donoghue JF, et al. Peripheral, central, and cross sensitization in endometriosis-associated pain and comorbid pain syndromes. Front Reprod Health. 2021;3:729642.

8. McKenzie A, Bittar T, Dombrower R, et al. Low-dose naltrexone in chronic pain management: mechanisms, evidence, and clinical implications. J Pers Med. 2026;16(3):151. doi:10.3390/jpm16030151.

9. Penn State Health. Low-dose naltrexone in combination with standard treatment in women with endometriosis (NCT03970330). ClinicalTrials.gov.

10. Kučić N, Rački V, Šverko R, et al. Immunometabolic modulatory role of naltrexone in BV-2 microglia cells. Int J Mol Sci. 2021;22(16):8429. PMID: 34445130.

11. Sullender RT, Silverstein RG, Goodwin DM, et al. Low-dose naltrexone as a treatment for vulvodynia: a case series. Case Rep Womens Health. 2025;45:e00677. PMID: 39802731.

12. Malutan AM, Drugan T, Costin N, et al. Pro-inflammatory cytokines for evaluation of inflammatory status in endometriosis. Cent Eur J Immunol. 2015;40(1):96-100. doi:10.5114/ceji.2015.50840.

About Dr. Kim

Dr. Yoon Hang "John" Kim is board-certified in Preventive Medicine with 20+ years of experience. Fellowship-trained at the University of Arizona Andrew Weil Center for Integrative Medicine (Osher Fellow). Certified in Medical Acupuncture (UCLA), Integrative & Holistic Medicine, and Functional Medicine. Specializes in LDN, autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, CFS/ME, MCAS, and mold toxicity. Author of 3 books and 20+ peer-reviewed articles. Professional site: www.yoonhangkim.com | Clinical practice: www.directintegrativecare.com